News

top of page

German Public Health Insurance Posts €2.6 Billion Surplus in First Half of 2026, But Underlying Deficit Persists as Hospital Costs Surge 9.3 Percent

German Public Health Insurance Posts €2.6 Billion Surplus in First Half of 2026, But Underlying Deficit Persists as Hospital Costs Surge 9.3 Percent

German Public Health Insurance Posts €2.6 Billion Surplus in First Half of 2026, But Underlying Deficit Persists as Hospital Costs Surge 9.3 Percent

Badari Andukuri

1 day ago

FDA Clears AstraZeneca's Etcamah for a Genetically Defined Subset of First-Line Breast Cancer | iPharmaCenter

FDA Clears AstraZeneca's Etcamah for a Genetically Defined Subset of First-Line Breast Cancer | iPharmaCenter

FDA Clears AstraZeneca's Etcamah for a Genetically Defined Subset of First-Line Breast Cancer | iPharmaCenter

Badari Andukuri

1 day ago

Ionis Wins First Ever FDA Approval for an Alexander Disease Treatment, Marking a Turning Point for a Disease With No Prior Options

Ionis Wins First Ever FDA Approval for an Alexander Disease Treatment, Marking a Turning Point for a Disease With No Prior Options

Ionis Wins First Ever FDA Approval for an Alexander Disease Treatment, Marking a Turning Point for a Disease With No Prior Options

Badari Andukuri

2 days ago

International Myeloma Society Annual Meeting | 2026

International Myeloma Society Annual Meeting | 2026

International Myeloma Society Annual Meeting | 2026

Badari Andukuri

3 days ago

European Commission | EMA Drug Approvals | 2026 | iPharmaCenter

European Commission | EMA Drug Approvals | 2026 | iPharmaCenter

European Commission | EMA Drug Approvals | 2026 | iPharmaCenter

Badari Andukuri

3 days ago

Pharmaceutical Healthcare Deals & Acquisitions - 2026 | iPharmaCenter

Pharmaceutical Healthcare Deals & Acquisitions - 2026 | iPharmaCenter

Pharmaceutical Healthcare Deals & Acquisitions - 2026 | iPharmaCenter

Badari Andukuri

5 days ago

European Society of Cardiology (ESC) Congress 2026 | News | Updates | iPharmaCenter

European Society of Cardiology (ESC) Congress 2026 | News | Updates | iPharmaCenter

European Society of Cardiology (ESC) Congress 2026 | News | Updates | iPharmaCenter

Badari Andukuri

6 days ago

INDIAN HEALTHCARE SYSTEM | HEALTHCARE SYSTEM OF INDIA | NEWS | BLOGS | IPHARMACENTER

INDIAN HEALTHCARE SYSTEM | HEALTHCARE SYSTEM OF INDIA | NEWS | BLOGS | IPHARMACENTER

INDIAN HEALTHCARE SYSTEM | HEALTHCARE SYSTEM OF INDIA | NEWS | BLOGS | IPHARMACENTER

Badari Andukuri

6 days ago

FDA Approves Takeda’s MIMRYLO for Polycythemia Vera | iPharmaCenter

FDA Approves Takeda’s MIMRYLO for Polycythemia Vera | iPharmaCenter

FDA Approves Takeda’s MIMRYLO for Polycythemia Vera | iPharmaCenter

Badari Andukuri

Aug 30

FDA Approves Revolution Medicines’ RASONQUE for Metastatic Pancreatic Cancer | iPharmaCenter

FDA Approves Revolution Medicines’ RASONQUE for Metastatic Pancreatic Cancer | iPharmaCenter

FDA Approves Revolution Medicines’ RASONQUE for Metastatic Pancreatic Cancer | iPharmaCenter

Badari Andukuri

Aug 27

China: NMPA Approves New Therapies | 2026

China: NMPA Approves New Therapies | 2026

China: NMPA Approves New Therapies | 2026

Badari Andukuri

Aug 26

FDA Approves Johnson and Johnson’s IMAAVY for Warm Autoimmune Hemolytic Anemia | iPharmaCenter

FDA Approves Johnson and Johnson’s IMAAVY for Warm Autoimmune Hemolytic Anemia | iPharmaCenter

FDA Approves Johnson and Johnson’s IMAAVY for Warm Autoimmune Hemolytic Anemia | iPharmaCenter

Badari Andukuri

Aug 26

Japan Approves GSK’s Hibsago for Chronic Hepatitis B and Takeda’s Orzeyful for Narcolepsy Type 1

Japan Approves GSK’s Hibsago for Chronic Hepatitis B and Takeda’s Orzeyful for Narcolepsy Type 1

Japan Approves GSK’s Hibsago for Chronic Hepatitis B and Takeda’s Orzeyful for Narcolepsy Type 1

Badari Andukuri

Aug 24

MHLW Japan | CHUIKYO Drug Price calculations | iPharmaCenter

MHLW Japan | CHUIKYO Drug Price calculations | iPharmaCenter

MHLW Japan | CHUIKYO Drug Price calculations | iPharmaCenter

Badari Andukuri

Aug 24

NICE Assessment Outcomes | 2026

NICE Assessment Outcomes | 2026

NICE Assessment Outcomes | 2026

Badari Andukuri

Aug 20

Regeneron's Pasatru wins FDA nod as second FOP therapy, first to cut flare-ups and new bone lesions

Regeneron's Pasatru wins FDA nod as second FOP therapy, first to cut flare-ups and new bone lesions

Regeneron's Pasatru wins FDA nod as second FOP therapy, first to cut flare-ups and new bone lesions

Badari Andukuri

Aug 20

Moderna Merck Collaboration News | iPharmaCenter

Moderna Merck Collaboration News | iPharmaCenter

Moderna Merck Collaboration News | iPharmaCenter

Badari Andukuri

Aug 19

NICE Backs Donidalorsen for Hereditary Angioedema and Acalabrutinib for Blood Cancers

NICE Backs Donidalorsen for Hereditary Angioedema and Acalabrutinib for Blood Cancers

NICE Backs Donidalorsen for Hereditary Angioedema and Acalabrutinib for Blood Cancers

Badari Andukuri

Aug 19

AstraZeneca–Daiichi Sankyo’s Enhertu Wins DESTINY-Lung04; HUTCHMED’s Tagrisso–Orpathys Pair Wins SAFFRON in MET-Selected EGFR NSCLC

Badari Andukuri

Aug 17

Top 10 Immunology Drugs by 2026 Revenue: Dupixent, Skyrizi and Rinvoq Lead

Badari Andukuri

Aug 17

bottom of page